Heartseed (219A) · InitiativeRestated
Expanding iPS cell technology and intellectual property into other fields
First written in FY2024. 2 of 3 entries say "Restated". Latest entry: 2026-03-27.
3entries
2years
1from disclosures
How it moved
Same theme, other companies
Expansion of Business Areas Centered on Regenerative MedicineA theme 7 companies write about · 0 as a headwind · 7 as a tailwind
1 other company's latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- 2026-03-27RestatedManagement Planning
「Expand into various regenerative medicine fields by leveraging our platform technology」
The Company reiterated its medium- to long-term policy of expanding its iPS cell-related platform technology beyond the cardiac field. - FY2025RestatedAnnual report
「These technologies may be used as platform technologies to expand the potential of iPS cell-based treatments beyond myocardial regeneration therapy.」
The Company continues to indicate the potential to use iPS cell technologies accumulated through myocardial regeneration therapy as a platform applicable beyond heart disease. - FY2024First statedAnnual report
「These technologies may be used as platform technologies to expand the potential of iPS cell-based treatments beyond myocardial regeneration therapy.」
The Company has indicated a policy of applying iPS cell-related technologies and intellectual property developed through myocardial regeneration therapy to fields beyond heart disease.